Expert opinion
Nicotinamide (vitamin B3) may help prevent skin cancer: positive phase 3 trial
11 January 2016
Dr. Andrew Chen, MBBS, from the Royal Prince Alfred Hospital at the University of Sydney in Australia and leader of the ONTRAC (Oral Nicotinamide to Reduce Actinic Cancer) phase 3 trial (1), says that “nicotinamide presents a new opportunity for the chemoprevention of non-melanoma skin cancers that is readily translatable into clinical practice.” Results from the ONTRAC trial with a cohort of 386 Australian adults indicate that a daily intervention dose of 500 mg nicotinamide (vitamin B3) for 12 months is protective against new cases of non-melanoma skin cancers.